Reckitt Benckiser makes out big time on the misery of U.S. flu sufferers

The fact that this flu season's vaccines were not very effective was bad news for people hoping to avoid the condition but great news for the U.K.'s Reckitt Benckiser Group, which racked up an impressive first quarter on sales of over-the-counter flu meds like Mucinex. Its Q1 sales were up 13%, its best quarter in a couple of years, Bloomberg reports. The rate of flu related hospitalization in the U.S. was twice what it was the year before, an example of how poorly the vaccines worked this year, as the flu mutated into different strains from those the vaccines targeted. RB this week had to recall 1.5 million bottles of Mucinex in the U.S. after discovering some bottles had faulty labels. Story | More | More

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.